SCHEMBL27034828

SCHEMBL27034828

CC(C)(C)OC(=O)N1CCC2(C1)CN(c1nc(C(F)F)cc3cnc(NC4CCN(S(=O)(=O)C5CC5)CC4)nc13)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 16/20 0.39
▸ CDK2 P24941 16/20 0.39
▸ CCND1 P24385 14/20 0.39
▸ CDK6 Q00534 14/20 0.39
▸ CDK4 P11802 5/20 0.37
▸ CCND3 P30281 5/20 0.37
▸ CCNT1 O60563 4/20 0.37
▸ CDK9 P50750 4/20 0.37
▸ CDK1 P06493 3/20 0.37
▸ CCNB1 P14635 2/20 0.37
▸ CDK7 P50613 2/20 0.37
▸ CCNH P51946 2/20 0.37
▸ MNAT1 P51948 2/20 0.37
▸ CCNE2 O96020 1/20 0.36
▸ RB1 P06400 1/20 0.36
▸ CCNA2 P20248 1/20 0.36
▸ KRAS P01116 1/20 0.36
▸ IDH1 O75874 1/20 0.36
▸ IDH2 P48735 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27034852 0.91 CCNE1 (0.42) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL30768118 0.91 CCNE1 (0.42) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL30768121 0.91 CCNE1 (0.42) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL27033396 0.87 CCND1 (0.41) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL27034849 0.82 CYP11B2 (0.41) CYP11B2GPR119
SCHEMBL30768105 0.82 CYP11B2 (0.41) CYP11B2GPR119
SCHEMBL30768122 0.80 CCNE1 (0.44) CCNE1CDK2CCND1CDK6
SCHEMBL27034827 0.80 CCNE1 (0.44) CCNE1CDK2CCND1CDK6
SCHEMBL30768124 0.80 CCNE1 (0.44) CCNE1CDK2CCND1CDK6
SCHEMBL31591035 0.80 CCNE1 (0.40) CCNE1CDK2CCND1CDK6CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250235456-A1 METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS IAMBIC THERAPEUTICS, INC. 2025-07-24 — — US disclosed
EP-4558502-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE Iambic Therapeutics, Inc. (US) 2025-05-28 — — EP disclosed
CN-120051470-A Azaquinazoline compounds and methods of use 依安彼克医疗有限公司 2025-05-27 — — CN disclosed
US-20240034731-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. 2024-02-01 — — US disclosed
WO-2024020419-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2024-01-25 — — WO disclosed
WO-2024020419-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2024-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034731-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE CCNI, CDKN1A, CDK8 CCNE1 47/4885CDK2 7/4885CCND1 39/4885
US-20250235456-A1 METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS AZI2, TPMT, HDAC10 CCNE1 423/4885CDK2 1208/4885CCND1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback